A Roundtable panel fielded a series of questions centering on whether single-use technologies had finally become “standard” for biopharmaceutical manufacturing, and if there were unforeseen benefits/disadvantages to the adoption of this technology. Max Blomberg, Executive Director of Operations, participated on behalf of Meissner, along with representatives from companies like Catalent, Advantapure, BioPlan Associates, Pharmatech Associates, and Sartorius.
